IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer’s Risk and Accelerate Early Detection July 10, 2025 Read More »
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights – A Year of Transformative Progress in Alzheimer’s Innovation June 30, 2025 Read More »
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30, 2025 June 27, 2025 Read More »
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon June 23, 2025 Read More »
IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market May 22, 2025 Read More »
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting May 12, 2025 Read More »
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer’s Innovation and AI-Driven Programs April 21, 2025 Read More »
IGC Pharma Expands CALMA Alzheimer’s Phase 2 Trial with Prestigious Research Site at Butler Hospital’s Memory and Aging Program April 8, 2025 Read More »
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health April 1, 2025 Read More »
